Fruquintinib improved survival in patients with refractory metastatic colorectal cancer

FHS
June 16, 2023
4:24 am

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.

World’s first completely open- and crowd-sourced neuroscience experiment launched

Today, scientists from the Allen Institute for Neural Dynamics, a division of the Allen Institute, launched the world’s first completely open- and crowd-sourced neuroscience experiment-;inviting

July 11, 2023

Heat-Related Texas Deaths Climb After Beryl Left Millions Without Power

SPRING, Texas — As the temperature soared in the Houston-area home Janet Jarrett shared with her sister after losing electricity in Hurricane Beryl, she did

July 23, 2024

Heidelberg Pharma AG Announces Updated Guidance – Biotech Investments

Heidelberg Pharma AG / Key word(s): Forecast Heidelberg Pharma AG Announces Updated Guidance 01-Oct-2024 / 15:27 CET/CEST Disclosure of an inside information acc. to Article

October 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.